Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 1 2Phase 3 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 14Gastrointestinal 13Genitourinary 11Dermatologic 10Breast 8Head & Neck 7Gynecologic 6Tumor-Agnostic 4Sarcoma 4Other hematologic neoplasm 4Other solid neoplasm 2Endocrine 2NET 1Lymphoid 1CNS 1

Conditions

Neoplasms 2Neoplasm Metastasis 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × avelumab × Tumor-Agnostic × Clear all
NCT03260023 2026-02-05

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Transgene

Phase 1/2 Active not recruiting
143 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT04266912 2025-11-25

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
23 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT03387111 2024-08-05

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

ImmunityBio, Inc.

Phase 1/2 Terminated
4 enrolled 14 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡